

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#12/A38  
8/28/02

In re the application of: Katherine Galvin, *et al*

Serial No.: 09/635,521

Group Art Unit: 1636

Examiner: Loeb, Bronwen

Filed: August 9, 2000

For: *METHODS AND COMPOSITIONS FOR THE  
DIAGNOSIS AND TREATMENT OF  
CARDIOVASCULAR AND TUMORIGENIC  
DISEASE USING 4941*

Attorney Docket No.: MNI-094

Commissioner for Patents  
Washington, D.C. 20231

**CERTIFICATE OF FACSIMILE TRANSMISSION**

I hereby certify that this correspondence is being facsimile transmitted to the Honorable Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

August 27, 2002

Date

Maria Laccotripe Zacharakis, Ph.D. Limited Recognition Under 37 CFR §10.9(b)

**AMENDMENT AND RESPONSE TO OFFICE ACTION**

Dear Sir:

This communication is submitted in response to the Office Action dated February 28, 2002 (Paper No. 9) which issued in the above-referenced application. A request for the appropriate extension of time is being submitted concurrently. In response to the Office Action, please amend the application as follows:

In the Claims: ✓

Please cancel claims 1-24 and 31-69, without prejudice, and amend claim 26 as follows:

26. (Amended) The method of claim 25, wherein the disorder is a disorder associated with aberrant angiogenesis.